Valeant Pharma (VRX) Tops Q2 Views; Raises FY10 Outlook
Tweet Send to a FriendGet Alerts VRX Hot Sheet
Price: $84.47 +13.12%
EPS Growth %: +31.3%
Financial Fact:
Net income per share attributable to Valeant: 0.39
Today's EPS Names:
ANF, DXLG, FL, More
EPS Growth %: +31.3%
Financial Fact:
Net income per share attributable to Valeant: 0.39
Today's EPS Names:
ANF, DXLG, FL, More
Trade VRX Now!
Valeant Pharmaceuticals (NYSE: VRX) reports Q2 EPS of $0.69, 6 cents better than the analyst estimate of $0.63. Revenue for the quarter was $255.6 million, which compares to the estimate of $239.22 million.
Raises its FY10 adj-EPS guidance from $2.65-$2.90 to $2.80-$3.05, vs. the consensus of $2.77.
Raises its FY10 adj-EPS guidance from $2.65-$2.90 to $2.80-$3.05, vs. the consensus of $2.77.
You May Also Be Interested In
- UPDATE: Bausch & Lomb near deal to sell to Valeant Pharmaceuticals (VRX) - WSJ
- Valeant (VRX) Continues Deal Hunt; Close to Buying Bausch & Lomb for $9B
- Ross Stores, Inc. (ROST) Reports In-Line Q1 EPS, Raises Guidance
Create E-mail Alert Related Categories
Earnings, Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
